107 related articles for article (PubMed ID: 20137620)
1. [Long-term therapeutic effect of Zenapax after renal transplantation].
Liu W; Ling JY
Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(36):2565-7. PubMed ID: 20137620
[TBL] [Abstract][Full Text] [Related]
2. [Half-dose Zenapax for acute rejection prevention after renal transplantation].
Zhu YS; Xu AP; He HX; Fan LP; Nie HB; Nv J; Hu WN; Li QR; Deng ZX
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Dec; 26(12):1818-20. PubMed ID: 17259129
[TBL] [Abstract][Full Text] [Related]
3. [Anti interleukin-2 receptor alpha antibodies (daclizumab) application for the treatment of kidney recipients].
Izvolskaja N; Rainiene T; Dainys B
Medicina (Kaunas); 2003; 39 Suppl 1():166-70. PubMed ID: 12761441
[TBL] [Abstract][Full Text] [Related]
4. Zenapax: transplant's first humanized monoclonal antibody.
Bell J; Colaneri J
ANNA J; 1998 Aug; 25(4):429-30. PubMed ID: 9791317
[No Abstract] [Full Text] [Related]
5. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.
Vafadari R; Quaedackers ME; Kho MM; Mol WM; Chan G; Weimar W; Baan CC
Transplantation; 2012 Sep; 94(5):465-72. PubMed ID: 22960764
[TBL] [Abstract][Full Text] [Related]
6. [Clinical effect of induction therapy with monoclonal antibodies after deceased-donor kidney transplantation (an experience from Vilnius Center)].
Rainiene T; Dobrovolskiene R; Dainys B; Kucinskis G; Zelvys A
Medicina (Kaunas); 2007; 43 Suppl 1():109-13. PubMed ID: 17551287
[TBL] [Abstract][Full Text] [Related]
7. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
[TBL] [Abstract][Full Text] [Related]
8. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Swiatecka-Urban A
Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
[TBL] [Abstract][Full Text] [Related]
9. Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation.
Garcia M; Weppler D; Mittal N; Nishida S; Kato T; Tzakis A; Ruiz P
Transplant Proc; 2004 Mar; 36(2):323-4. PubMed ID: 15050146
[TBL] [Abstract][Full Text] [Related]
10. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.
Gabardi S; Catella J; Martin ST; Perrone R; Chandraker A; Magee CC; McDevitt-Potter LM
Ann Pharmacother; 2011 Sep; 45(9):e48. PubMed ID: 21811001
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of induction therapy with anti-interleukin-2 receptor antibodies or thymoglobulin compared with no induction therapy in renal transplantation.
Taber DJ; Weimert NA; Henderson F; Lin A; Bratton CF; Chavin KD; Baliga PK
Transplant Proc; 2008 Dec; 40(10):3401-7. PubMed ID: 19100399
[TBL] [Abstract][Full Text] [Related]
12. Induction immunotherapy with IL-2Ra monoclonal antibody in kidney transplantation.
Ahsan N
Minerva Urol Nefrol; 2003 Mar; 55(1):67-79. PubMed ID: 12773968
[TBL] [Abstract][Full Text] [Related]
13. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.
Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber LW; Gaber AO
Transpl Int; 2001 Dec; 14(6):396-404. PubMed ID: 11793037
[TBL] [Abstract][Full Text] [Related]
14. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period.
Lauro A; Amaduzzi A; Dazzi A; Ercolani G; Zanfi C; Golfieri L; Grazi GL; Vivarelli M; Cescon M; Varotti G; Del Gaudio M; Ravaioli M; Siniscalchi A; Faenza S; D'Errico A; Di Simone M; Pironi L; Pinna AD
Dig Liver Dis; 2007 Mar; 39(3):253-6. PubMed ID: 17275428
[TBL] [Abstract][Full Text] [Related]
15. [Clinical study of three-dose regimen of Zenapax in orthotopic liver transplantation].
He G; Yu LX; Deng WF
Di Yi Jun Yi Da Xue Xue Bao; 2004 Jul; 24(7):729-32. PubMed ID: 15257886
[TBL] [Abstract][Full Text] [Related]
16. No induction versus anti-IL2R induction therapy in simultaneous kidney pancreas transplantation: a comparative analysis.
Becker LE; Nogueira VA; Abensur H; Miranda MP; Genzini T; Romão JE; Noronha IL
Transplant Proc; 2006; 38(6):1933-6. PubMed ID: 16908327
[TBL] [Abstract][Full Text] [Related]
17. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
Zanfi C; Lauro A; Cescon M; Dazzi A; Ercolani G; Grazi GL; Zanello M; Vivarelli M; Del Gaudio M; Ravaioli M; Cucchetti A; Vetrone G; Tuci F; Di Gioia P; Lazzarotto T; D'Errico A; Bagni A; Faenza S; Siniscalchi A; Pironi L; Pinna AD
Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276
[TBL] [Abstract][Full Text] [Related]
18. [Interleukin-2 receptor blockers in renal transplantation].
Basić-Jukić N; Bubić-Filipi L; Danić A; Pasini J; Kes P
Acta Med Croatica; 2004; 58(5):395-9. PubMed ID: 15756806
[TBL] [Abstract][Full Text] [Related]
19. Anti-IL-2 receptor antibody vs. polyclonal anti-lymphocyte antibody as induction therapy in pediatric transplantation.
Di Filippo S
Pediatr Transplant; 2005 Jun; 9(3):373-80. PubMed ID: 15910396
[TBL] [Abstract][Full Text] [Related]
20. The outcome of induction therapy with monoclonal antibodies in kidney transplantation among Iranian patients: a prospective study.
Naderi GH; Mehraban D; Ganji MR; Jafarpouriani M; Latif AH
Transplant Proc; 2009 Sep; 41(7):2768-71. PubMed ID: 19765430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
